ABSTRACT: Long-acting opioids are prescribed as part of treatment for opioid use disorders; methadone and buprenorphine are well researched and commonly prescribed for the treatment of opioid use disorder. Meta-analysis suggests that buprenorphine has a slightly poorer retention rate in treatment as compared to methadone. Benefits of buprenorphine/naloxone include greater ease in ceasing treatment and less use of illicit opioids while in treatment as compared to methadone. There are a number of qualitative and mixed-method studies that ask patients about their experiences of methadone maintenance and buprenorphine maintenance treatment. This research aimed to understand perspectives of receiving buprenorphine/naloxone for the treatment of opioid use disorder. A qualitative descriptive approach was used. Seven participants with a current diagnosis of opioid use disorder treated with buprenorphine/naloxone were interviewed. Thematic analysis extracted four themes: drivers for opioid substitution treatment change; readiness for buprenorphine/naloxone substitution treatment; absence of effect from buprenorphine/naloxone; and an increased sense of citizenship on buprenorphine/naloxone. This study identified a number of factors influencing participants' decision-making in transferring between methadone and buprenorphine/naloxone for the treatment of their opioid use disorder. Methadone was preferred by those seeking sedation and wishing to continue using other opioids, and buprenorphine/ naloxone was most effective for participants no longer wishing to experience sedation and seeing opioid abstinence as an end point in their recovery. Changing treatment expectations are important to consider when determining medication selection and highlight the importance of quality information when determining the most suitable medication for the treatment of opioid use disorder.
INTRODUCTION
Opioid use disorder is a long-term relapsing condition where individuals find it difficult to cut down or stop using opiates or opioids despite their best efforts. Negative outcomes include bloodborne viruses and acute and long-term mental health and physical health issues (NICE 2007; Stein et al. 2001) . Opioid use disorder has four diagnostic criteria groupings, namely 'impaired control, social impairment, risky use, and pharmacological criteria' (American Psychiatric Association 2013, p. 483) , and a set of diagnostic criteria, including but not limited to problematic use patterns that result in substantial levels of impairment or distress. People requesting treatment include those who purchase opioids from an illegal market, those who gain opioids from physicians in increasing doses, and those who illegally gain access to fraudulently use prescriptions (Johnston et al. 2010; Larson & Bammer 1996; Zacny et al. 2003) . Most individuals will experience increasing tolerance and then withdrawal following the cessation of opioids, along with a psychological and conditioned response to any further exposure to opioid related stimuli long after physical withdrawal has ended (American Psychiatric Association 2013).
Opioid substitution treatment (OST) is the most effective form of treatment for opioid use disorders with long-acting opioids (LAOs) being the most often used medications with methadone, buprenorphine (BUP), and buprenorphine/naloxone (BUP/NX) being frequently prescribed and researched (Faggiano et al. 2003; Mattick et al. 1998) . Buprenorphine alone has mostly identical properties to BUP/NX, and most research around this LAO is based solely on the buprenorphine component, so at times buprenorphine will be referred to. Naloxone was added to buprenorphine as a deterrent to injecting because when injected the naloxone component will put the user into opioid withdrawal (National Institute on Drug Abuse 2002).
The New Zealand Guidelines for Opioid Substitution Treatment (MoH 2014) do not recommend rapid detoxification from opioids as it is an ineffective approach for the majority of opioid users, with high rates of relapse and mortality (Ministry of Health 2014) . Most countries take a maintenance approach to opioid use disorder as a harm reduction approach (Mattick et al. 2014) . Reduced harm is achieved through replacing or substituting short-acting opioids with LAOs (Mattick et al. 2014) . Opioid cravings are reduced with LAOs, and stability is achieved by preventing intoxication and withdrawal from opioids (Mattick et al. 2014) .
Methadone is a well-researched and comprehensively prescribed treatment for opioid use disorder since the 1960s, when Dole and Nyswander (1967) prescribed methadone with an ongoing high-dose approach (doses greater than 60 mg). Buprenorphine/ naloxone has been used increasingly for the treatment of opioid dependence since the mid-2000s but has only been available as a subsidized medicine in New Zealand through PHARMAC (New Zealand's Pharmaceutical Management Agency) since the late 2013 (Ministry of Health 2014) . This study will refer to those seeking OST treatment as patients. The participants refer to social inclusion as being important in their recovery. In the study, citizenship is contextualized as social inclusion and highlights how the treatment pathways for opioid substitution contribute or detract from a sense of inclusion in a civil and social capacity. Harm reduction and recovery are part of a continuum (White & Cloud 2008) . Where a harm reduction approach aims to minimize mortality, criminality, bloodborne viruses, physical health issues, and other social harms, a recovery approach aims to enhance employment opportunities and living conditions, improve social connections, and strengthen relationships with friends and family (White & Cloud 2008) . The recovery approach also aims to instil a sense of hope and improve a person's ability to cope with life stressors (Bamber 2010) . Patients of services providing OST benefit from a service that aims to reduce harms and deliver a recovery-oriented service. This includes the view that those clinicians deliver a recoveryoriented service and include within their mindset the idea that the patient can reach a point whereby they can successfully come off OST. Recovery can be said to be occurring while a person is undertaking varying degrees of ongoing substance use, and occurs in a state of abstinence (Bamber 2010) .
BACKGROUND
Preferences for using buprenorphine and/or methadone have been researched in the UK and the United States with consistent findings (Pinto et al. 2010; Schwartz et al. 2008) . Schwartz et al. (2008) found there were few negative attitudes in the United States towards buprenorphine as compared to methadone from those seeking treatment. They suggest there is stigma attached to methadone that is not associated with buprenorphine. In the UK Summit trial (Pinto et al. 2010) , 361 participants were surveyed; 134 participants chose buprenorphine, and 227 chose methadone. The main reasons for choosing buprenorphine, after the belief that it was less stigmatizing, was its ability to block the effects of heroin, and that buprenorphine was perceived as having less withdrawal effects when tapering off. The reasons for choosing methadone included positive experiences of methadone, the fear of having to be in withdrawal to start buprenorphine, the intoxicating effects of methadone, and being on too high a dosage of heroin to take buprenorphine. Cunningham et al. (2013) interviewed 87 patients about buprenorphine and found in addition to the above points that prior experience of buprenorphine was associated with better retention in treatment.
Patients' perspectives of various treatment settings for the provision of OST have also been studied. Within New Zealand, the two main settings for OST are specialist addiction services and primary-based services (Ministry of Health 2014). Primary services are considered from a clinical and policy perspective as being cost-effective and more efficient as comprehensive primary care can be provided in conjunction with OST (Arfken et al. 2010 ; Ministry of Health 2014). Stancliff et al.'s (2012) study on attitudes towards OST found that buprenorphine was most appropriate for those people who wanted to stop illicit opioid use and that participants felt they had more control over their treatment on buprenorphine as opposed to methadone because of less stigma from pharmacists, prescribers, family, and others.
When patients talk about recovery, many identify coming off OST as a crucial point in their treatment (Bamber 2010) . Winstock et al. (2011) conducted a cross-sectional survey of 145 people receiving OST in New South Wales. Sixty-two per cent considered coming off in the next 6 months. Respondents who previously attempted to come off, usually through the process of 'jumping off' (rapidly titrating the dose down), wanted to reduce the dosage slowly through a doctor-led or self-managed reduction.
Two meta-analyses demonstrate that both long-term provision of methadone and the long-term provision of either buprenorphine or BUP/NX are more effective than no treatment, or short-term managed withdrawal (Barnett et al. 2001; Mattick et al. 2014) . Retention in treatment from methadone was found to be better than buprenorphine or BUP/NX because the increased adherence to methadone extends the time in treatment and improves stability around opiate use (Mattick et al. 2014) . There are anecdotal reports that these medicines have different qualities; namely, methadone sedates and reduces motivation for some, and buprenorphine provides a mental clarity and energizing effect (Pinto et al. 2010) . These reports match the pharmacodynamics of each medicine; methadone is a long-acting full agonist and buprenorphine is a long-acting partial agonist, meaning that methadone's effects are similar to other opioids and buprenorphine's effects are unique to buprenorphine (Mattick et al. 2014) . The Summit trial demonstrates that methadone is easier to remain on and those on buprenorphine are less likely to use other opioids illicitly (Pinto et al. 2010) .
Much of the research comparing methadone and buprenorphine or BUP/NX has focused on retention in treatment, relative risks of treatment, and the degree of ongoing illicit opioid use while in treatment (Bell et al. 2009; Gryczynski et al. 2013; Kakko et al. 2007 ). There are a number of qualitative and mixed-method studies that ask patients about their experiences of methadone maintenance and buprenorphine maintenance treatment (Cunningham et al. 2013; Madden et al. 2008; Stancliff et al. 2012) . One study that did examine patient experiences asked 90 patients from Lanarkshire, Scotland, to compare methadone to BUP/ NX (Hill et al. 2014) . Their participants' experiences of BUP/NX are consistent with the experiences discussed within this research; namely, the participants were positive about their experiences, and the advantages of BUP/NX over methadone included 'the "clear-headed response", improved well-being and concentration, possibility of less social stigma, reduced craving, decreased side effects (especially drowsiness) and easier to withdraw from' (Hill et al. 2014, p. 173) .
Methadone, buprenorphine/naloxone, and their effects on the endocrine system Opioid use androgen deficiency results from long-term opioid therapy, whereby the endocrine system is suppressed. This can lead to hypogonadism, osteoporosis, and alterations to the hypothalamic-pituitary-adrenal axis and the hypothalamic-pituitary-gonadal axis (Elliott & Fibuch 2013; Gudin et al. 2015) . The impairment of the endocrine system by way of long-term opioid use or treatment, known as endocrinopathy, is experienced through symptoms such as impaired sexual function, low mood, a loss of libido, and osteoporosis (Baldini et al. 2012; Brennan 2013; Elliott & Fibuch 2013; Gudin et al. 2015) . Endocrinopathy has been identified specifically in people receiving long-term methadone treatment (Bawor et al. 2014; Trajanovska et al. 2013) .
The effect of endocrine suppression is especially prevalent in men because it is so closely related to testosterone levels (Bawor et al. 2014) . Low plasma testosterone is the primary marker for endocrinopathy, and Bliesener et al. (2005) identified that those prescribed buprenorphine maintained their plasma testosterone and were less likely to experience symptoms related to low testosterone than those being prescribed methadone.
Methadone, buprenorphine/naloxone, and their cognitive effects
The neuropsychological aspects of opioid use, which result in cognitive impairment, have been extensively researched (Walker & Zacny 1998; Walsh et al. 2008; Zacny 1995; Zacny & Gutierrez 2011 ). This cognitive impairment while on opioids is no different to those who are on long-term methadone or buprenorphine, and those participants also display impairment around processing speed, and executive functioning in the short term (Darke et al. 2012) . Long-term use, though, does appear to result in those on buprenorphine experiencing less cognitive impairment than those on methadone in the measures of psychomotor speed, working memory, divided attention, reaction speed, and verbal memory (Rapeli et al. 2011; Soyka et al. 2011) . The rationale for buprenorphine leading to less cognitive impairment over the long term has been suggested as a result of buprenorphine being a partial agonist and thus only partially impacting on cognitive function when compared to full agonists such as methadone or heroin (Soyka et al. 2001) .
METHODS

Aim
The study aim was to describe patients' perspectives of BUP/NX, their decision-making, and events that contributed to medication choices.
Design
This research used a qualitative descriptive design and was interview-based with open-ended questions. Inherent within qualitative description there is an intent that the researcher remains as close as they can to the 'surface of the data and events' (Sandelowski 2000, p. 336). Qualitative description intends to give 'a rich description of the experience depicted in easily understood language' (Sullivan-Bolyai et al.
2005, p. 128).
Ethical considerations
The study was approved by the University Human Ethics Committee (Application number: 14/102). The lead author had a previous clinical involvement with the potential participants' addiction treatment, but did not have current clinical involvement with participants who were interviewed for this research. The conflict of interest was managed by (i) avoiding providing treatment advice to participants during interviews, (ii) keeping research information confidential from clinicians from the service, (iii) anonymized research findings, and (iv) no involvement in clinical discussions.
Participants
This study collected data from patients experiencing opioid use disorder, who have an active diagnosis for opioid use disorder and are receiving treatment. Potential participants were contacted by an intermediary person and invited to participate in the study. Recruitment and data collection ran in parallel over a 12-week time frame. Participants needed to have been prescribed BUP/NX. People experiencing active psychotic symptoms or under 18 years of age were excluded. All the participants' details were anonymized and have been given pseudonyms. The participants refer to as BUP/NX by its brand name Suboxone â in this study.
Seven individual interviews were conducted with five male and two female participants. Two participants were M aori, and five were European New Zealanders. Ages ranged from 25 through to 65. Written consent was sought prior to each interview. Five participants had 'transferred' from methadone to BUP/NX, one started directly on BUP/NX, and one had transferred from BUP/NX to methadone. Five had previously tried BUP/NX prior to the most recent transfer. Six randomly selected patients who were approached to participate had switched from BUP/NX to methadone, did not want to be sent the information sheet, and did not want to participate in the study. Six participants had chosen to transfer medication themselves, and one participant was transferred from methadone to BUP/NX due to health complications associated with methadone that meant staying on methadone was no longer possible. Opioid substitution treatment is a voluntary treatment, and participants were not compelled to receive any form of OST.
Data collection
Participants were sent the main interview questions in advance. All participants were asked:
• What led to you seeking treatment?
• What led to you being prescribed Suboxone?
• What were you hoping for from this treatment?
• What would your advice be for others commencing treatment?
They were then asked focused questions to explore issues further. The interview duration was between 50 and 60 min. The interviews were recorded and transcribed. Following the interviews, each participant received a copy of their transcript for checking.
Data analysis
An interpretive thematic analysis was used to make sense of the data. This approach is informed by the work of Braun and Clarke (2006) and seeks to identify, order, and interpret the collected data. Along with its use of coding, qualitative descriptive data analysis draws on another element of naturalistic research known as inductive enquiry (Elo & Kyng€ as 2008) . Inductive enquiry extracts themes and concepts from the data as they appear, and is of benefit when little is known about a particular phenomenon (Braun & Clarke 2006) . Four main themes were established in the analytic process, and these themes were settled on by ordering twelve particular codes. For example, the theme of drivers for opioid substitution treatment change resulted from combining several codes to do with frustration towards a particular medicine and its effects, a desire to change from being 'tethered' to a particular medicine, and to attending the pharmacy under a presumptive stigma. The codes were defined as follows: stigma, a loss of control, sedation, and feeling their medication was 'just another drug'.
Rigour and trustworthiness
Rigour and trustworthiness mean to show competence and integrity in order to establish the research project as a legitimate representation (Tobin & Begley 2004) . The participants were selected for their experience of the phenomenon, and the multiple realities conveyed as accurately as possible. The data have been described in detail to allow the reader to determine the transferability of the findings. A wide range of quotes from all the participants throughout the research findings are included in the research account. The research in this study is auditable; recorded interviews were transcribed and member-checked (i.e. participants had the opportunity to review the transcripts for factual accuracy), and the research was peer-reviewed from a methodological and content perspective.
RESULTS
Four themes were extracted once the transcripts were coded and analysed from the interview data:
• Drivers for opioid substitution treatment change.
• Readiness for BUP/NX substitution treatment.
• Absence of effect from BUP/NX.
• An increased sense of citizenship on BUP/NX. Despite the participants having very different pathways into treatment, they shared some very similar perceptions and experiences when it came to discussing their decision matrix with regard to transferring between methadone and BUP/NX.
Drivers for opioid substitution treatment change
This theme focused on descriptions of what led the participants to consider trying BUP/NX for the treatment of their opioid use disorder. The discussion is structured using the subthemes of stigma, loss of control, and the effects of the medication. These subthemes represent important drivers for changing from methadone to BUP/NX for the participants.
Stigma as it relates to the research topic is the personal feeling of disgrace or disapproval when experiencing an opioid use disorder and accessing treatment services for that use disorder. Several participants discussed how their own sense of stigma was associated with methadone. Jared, who had unsuccessfully tried BUP/NX and transferred to methadone, articulated how the pathway through illicit opioid use and onto treatment led to a state of self-criticism: 'I'm really ashamed. . . I kick myself because of the stupidity of getting into opiates in the first place'.
Participants also felt stigmatized because of the behaviours they had witnessed from others who were receiving methadone substitution treatment. Bob was especially frustrated with people being prescribed methadone trying to buy off him, or sell him illicit substances. Participants also experienced a sense of stigma from other members of society. Ted talked about how 'the stigma of having family who have judged me for being on that medication'. All the participants articulated the view that BUP/NX carried less negative connotations than methadone. Tom likened methadone to being a legally sanctioned 'fix', as there was a reputation amongst opioid users as simply another way to get 'high', 'whereas Suboxone is just like taking a vitamin in the morning. You lose that stigma'.
The administration of methadone and BUP/NX for the treatment of opioid use disorder is tightly controlled, with those in treatment having to attend the pharmacy to consume their medicine in front of a pharmacist. Three participants talked about methadone leading to a loss of control. They all interpreted this loss of control as an outcome of being on a controlled substance for the treatment of opioid use disorders that had a high abuse potential. These three participants said their perception of methadone was based on their own histories of methadone use that included frequent double dosing and injecting. Their reticence towards having to attend the pharmacy every day came from the factors such as having no desire to be around people who were still caught up in drug dealing, and feeling like they were being judged by pharmacists and other customers at the pharmacy.
The physical effects of methadone, and especially the sedative effects, were noted by all seven participants. Tom was also concerned about respiratory depression from methadone, and QTc prolongation (a cardiac condition related to higher doses of methadone, which can increase the risk of heart failure). Ruth felt there was a risk of getting 'stuck' on methadone because, simply put 'it sticks around'. Ruth reflected on methadone as both a saving grace and a trap: 'They call it "liquid handcuffs" and it is really'. Dave stated that it was easier to come off BUP/NX than off methadone, and once off, he returned to his 'normal self' quicker coming off BUP/NX. For Jared, this awareness that it is difficult to 'come off' methadone was a positive thing at present. It was, in his eyes, the long-acting and hard-to-leave effects of methadone that kept him stable. These participants noted that as the benefits of their methadone, in terms of their treatment, reduced, their old compulsive behaviours pertaining to opioid use returned. While being prescribed methadone, Bob was finding himself getting to the pharmacy earlier every day, until the point he was there waiting for them to open.
Readiness for BUP/NX substitution treatment: 'A chance to get your head around things'
This theme focuses on the participant's considerations of what it means to be 'ready' to take BUP/NX, and for the beneficial effects as an opioid substitution treatment. Participants experienced methadone as having mostly similar effects to other opioids when compared to BUP/NX. Because BUP/NX was seen as so different in its effect, all participants felt that it took longer to adjust to. Bob talked about needing to be 'fully committed to Suboxone â for it to work'. Bob saw commitment as giving treatment a chance, perhaps engaging in case management, psychology, group work, or even just giving things a bit of time to change.
Both Tom and Bob talked about how after commencing BUP/NX they experienced a flood of anxiety and emotions associated with the underlying causes of their opioid use disorder. Tom talked about how his family members and clinical team had prepared him for this, and because he expected it, he was able to get through the first 6 months on BUP/NX and 'ride out' his increased anxiety once off methadone and other central nervous system (CNS) depressants.
While many of the participants had made reference to the notion of being ready for BUP/NX to benefit from it, Jared explained that he was not 'ready' for the BUP/NX he was started on. On reflection, Jared contended that he still wanted to use 'turned morphine' (morphine that has been chemically altered to resemble a heroin molecule) when he started treatment on BUP/NX, and lamented not 'giving it a better go' because now he has to manage the intrusive side effects of methadone such as sweating, less motivation, and less energy. Ruth was transferred onto BUP/NX after a prolonged hospitalization and thought she would miss out on the dreamy, daze-like feeling that she experienced on methadone. However, she said 'I came out of my daze and quite liked not being in a daze'. She said she became much happier than she could ever remember. Ruth said that although she never wanted 'to go on Suboxone â ', it worked.
Absence of effect from BUP/NX: 'I'm not muddled or befuddled'
This theme relates to the differences the participants noticed since 'transferring' to BUP/NX when compared with their experiences of methadone. Participants talked about feelings of increased clarity on BUP/NX. Unlike methadone, which they experienced as clouding thinking and slowing them down, participants experienced little or no effect when taking BUP/NX. 'Yeah, as I said I really can't feel it in my system . . . I'm not muddled or befuddled by the drug. (Dave)'. Bob associated his new found clarity on BUP/NX with improving his decision-making abilities: 'You can still think clearly to make decisions, proper decisions. Which I'd never made on methadone'. The change in medication from methadone to BUP/NX led to more subtle changes for Dave in that he experienced his relationships, social interactions, and emotional states more 'vibrantly'.
Participants all reported less need for getting to the pharmacy as soon as possible, or being motivated to increase, or double up on their dose of BUP/NX. Dave noted: 'I think less craving with Suboxone â . . . I feel OK. Not stressed about it'. Both Tom and Ruth articulated that there were pharmacological reasons for this. Ruth pointed out that BUP/NX has 'got a ceiling on it. It's not like the methadone where you can go up and up and up; it levels off'. Participants stated that transferring to BUP/NX cannot just be considered as merely psychological in origin and that BUP/NX has very different pharmacological effects on the self when compared to the effects they experienced from taking methadone.
An increased sense of citizenship associated with a transfer to BUP/NX: 'It just kind of crept up on me since the change'
The final theme pertains to the participants' increased sense of citizenship since their transfer to prescribed BUP/NX. Previously, Bob perceived the only useful treatments were based solely on pharmacotherapy, and more equalled better, he now considers pharmacotherapy as only one part of a wider treatment approach. Reflecting on his transfer to BUP/NX, Bob stated: 'It's making me cope and look at what I've got to actually do. I've got to sort out the underlying issues; it's not so much the drugs'. Tom decided to shift to BUP/NX to ameliorate a state of sedation: 'once you've been in kind of an opiate induced haze for a long period of time it is kind of like, it's like being in a bubble'. He opted out of 'being in the bubble' and instead committed to psychological supports. Ruth, Bob, and Tom all said that as they approached their substance use without a motivation to become as sedated as they possibly could, they were increasingly keen to access other therapies and in turn had a better sense of self. A number of the participants talked about the difference between methadone and BUP/NX, and how it impacted on their ability to consider or do work and study. Ruth said that for the first time in 40 years, she has got a job. She had in the past contemplated work, but never could get herself past the application phase, let alone attend an interview:
Before when I was on methadone, I went for a job and I got all these bits of paper and I thought well I can't be stuffed filling these out. This time I filled them all out and then got a job. So that's the difference.
Tom had always worked while being on methadone, but since starting BUP/NX, he talked about it having a broader impact. He improved in his workplace interactions which allowed him to maintain better relationships with his colleagues. He talked about getting on top of his finances, not seeing 'a stack of twenties as being a certain amount of a drug', but rather seeing money as something that enabled him to travel, eat well, and live well. Bob talked about now having a 2-year plan for work and study. He stated that he now wants to communicate with his tutors and this helps him work out what he needs to do for his studies, something that had not been the case previously.
DISCUSSION
Multiple factors influenced the decision-making of the research participants when they considered transferring between methadone and BUP/NX. Stigma was one factor for considering options apart from methadone, as had been identified by other studies (Deering et al. 2012 (Deering et al. , 2014 Yarborough et al. 2016) . Methadone carried a negative label, and Harris and McElrath (2012) point out that this has led people to prematurely drop out of treatment. Gryczynski et al. (2013) reported people in New York City returning to treatment when primary service-initiated BUP/NX was made available because they perceived that they could re-enter treatment without being stigmatized.
Methadone effects also shaped decisions to transfer from methadone to BUP/NX. These effects are threefold and fit with the pharmacodynamic and neuropsychological literature. Firstly, there is a sedative effect as methadone is a long-acting central and autonomic nervous system and depressant and derives its sedative, anaesthetic, and ataractic effects from this mode of action (Chou et al. 2015) . Secondly, there is loss of motivation: methadone and most full-agonist opioids interact with the endocrine system and lower testosterone levels (Gudin et al. 2015) . Thirdly, methadone arguably has measurable cognitive impairing effects resulting in reduced conceptual flexibility and increased perseverative responses (Walsh et al. 2008) . According to some participants, the stabilizing benefits of methadone were outstripped by a loss of motivation, cognitive impairment, and emotional dysregulation. These participants contended that after transferring from methadone to BUP/NX, they experienced increased motivation, their thinking became clearer, and they were less likely to get frustrated or have a 'short fuse'.
Participants talked about how their focus of opioid use disorder treatment had shifted from a point of stabilizing and harm reduction towards broader goals of recovery once transferring to BUP/NX. They were at a point where the harm reduction benefits from being on methadone had 'run its course', and they were now considering what contributed to their disorder, and were prepared to do the psychological work required. Opioid substitution treatment then becomes part of a wider treatment approach shifting from associating beneficial treatment with familiar medication effects to associating beneficial treatment with psychological therapies and lifestyle change, and medications with an absence of effect.
Participants referred to possessing a 'readiness' for BUP/NX for it to be effective for the treatment of their opioid use disorder. In pharmacodynamic terms, buprenorphine is a partial agonist on the mu-opioid receptor and has a weak effect on the kappa-opioid receptor (Khroyan et al. 2014) . Further research and enquiry into the notion of 'readiness' as it relates to 'absence of effect' would help inform decision-making as to the ability to tolerate BUP/NX-based OST. One participant was transferred to BUP/NX due to health complications associated as with methadone and mutually agreed to this transfer. Interestingly, this participant noted an underlying readiness they were not aware of prior to their transfer to BUP/NX.
The participants' assertions that they were more able to engage in difficult cognitive tasks once transferring to BUP/NX are also supported by the data that demonstrate BUP/NX having less cognitively impairing effects when compared with methadone over the long term (Rapeli et al. 2011; Soyka et al. 2011) . Furthermore, the participants in this study considered that their clearer thought processes allowed them to achieve things they otherwise would not have attempted. The improvements they noted ranged from an ability to read and remember things, through to returning to more challenging employment opportunities, study goals, and social situations.
In addition to the cognitive improvements the participants reported when transferring from methadone BUP/NX, they had a lift in energy and motivation. Lower plasma testosterone has been linked to hypogonadism and endocrinopathy, both conditions present with symptoms such as reduced motivation, low energy, and impaired sexual function (Bawor et al. 2014; Trajanovska et al. 2013) . Buprenorphine/naloxone appears to have less of an effect on the endocrine system when compared to methadone and other long-acting full-agonist opioids (Rapeli et al. 2011) .
The participants of this study described at points in their treatment that they had a desire to experience sedation, and as such considered methadone very beneficial. For most, though, at a certain point the loss of motivation and low energy outstripped any perceived benefits related to sedation. The option of transferring to BUP/NX was not without its problems for the study's participants, though, as they discussed an emergent emotional rawness that surfaced once they ceased methadone. Further research is recommended to look at the emotional 'tipping point' during substitution treatment for opioid use disorder whereby the patient is motivated to expose themselves to the stressors they had previously attempted to suppress.
When weighing up the options of methadone and BUP/NX, the imperative of treatment delivery is to consider the psychosocial, emotional, and pharmacological parameters as detailed in a model titled The Opioid Use Disorder Treatment Decision Triangle (see Fig. 1 ). The Opioid Use Disorder Treatment Decision Triangle was developed from the results of this research with patients' expressions that pharmacological, emotional, and psychosocial factors impact on their decisions around accessing methadone or BUP/NX. The Opioid Use Disorder Treatment Decision Triangle is intended to fit within the recovery model informed by the concepts of harm reduction, recovery, and citizenship. The central component of the pyramid is the Patient Seeking Opioid Substitution Treatment. The lower left component -Pharmacological -refers to the pharmacological impacts each of methadone and BUP/NX. These include all the documented side effects of both medications as discussed previously and also include other pharmacological considerations which may affect the choice of medication, such as QTc prolongation (an unpredictable heart rhythm side effect related to methadone) that renders methadone risky for some (Krantz et al. 2009 ). The lower right component -Emotional and Psychological -refers to and emphasizes the importance of the emotional and psychological readiness cited by the participants of this study for BUP/ NX to provide a beneficial effect. The top component of the model -Social -relates to the myriad of social factors that impact on decision-making, including stigma, the patient's theories of substance use, their definition of recovery, and the social systems around them. A set of decision questions informed by the research findings are detailed in Table 1 . This model is suited to mental health nurses and other clinicians and for those seeking opioid substitution treatment at the key decision points in treatment when medication or changes in medication are being considered.
Limitations
This study has several limitations. Although after seven interviews there was commonality across the data, the number of interviews is small and the findings are specific to the people interviewed. All the participants were vocal about the benefits of BUP/NX, and that could be considered a limitation, as there was an unwillingness of people who had transferred from BUP/NX to methadone to participate in the research. Therefore, the researcher was unable to establish any thematic concepts around why people may have transferred from BUP/NX to methadone. The researcher's professional clinical role in substance use treatment may also have influenced the responses of the participants as once the interviews commenced, it was clear that a number of the participants were aware of the researcher's clinical involvement with their treatment service.
CONCLUSION
Stigma is a driver for transferring from methadone to BUP/NX, as are the reinforcing effects of methadone as experienced by this study's participants. For these participants, opioid treatment expectations changed over time as those accepting treatment experience their recovery as more than a reduction in harm, move towards wanting treatments that are nonsedating, and require more self-efficacy to enhance their well-being. Participants report that transferring between methadone and BUP/NX is a complex interplay between distinct psychosocial, pharmacological, and emotional factors (in particular, an exacerbation of anxiety). These findings are comparable with previous research on OST, and the rich descriptions of the study's participants shed some light on the emotional complexities that factor in medication change. This study concludes that where the participants were up to in their recovery journey, and shifts in treatment expectations are important factors to consider when determining medication selection for those seeking treatment for an opioid use disorder. This study also concludes that when measuring the effectiveness of OST, the reduction in mortality and in bloodborne viruses only tells part of the story in terms of benefit. Recovery and shifts in treatment expectations are also important factors to consider when determining the effectiveness of treatment for opioid use disorders.
RELEVANCE TO CLINICAL PRACTICE
The provision of quality information when determining the most suitable medication for the treatment of opioid use disorder is important. A treatment model for informing decision-making with a client when considering whether methadone or BUP/NX is more appropriate has been provided. 
